DOP2018000262A - Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales - Google Patents

Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales

Info

Publication number
DOP2018000262A
DOP2018000262A DO2018000262A DO2018000262A DOP2018000262A DO P2018000262 A DOP2018000262 A DO P2018000262A DO 2018000262 A DO2018000262 A DO 2018000262A DO 2018000262 A DO2018000262 A DO 2018000262A DO P2018000262 A DOP2018000262 A DO P2018000262A
Authority
DO
Dominican Republic
Prior art keywords
animals
treatment
diseases
indazols
prevention
Prior art date
Application number
DO2018000262A
Other languages
English (en)
Inventor
Bothe Ulrich
Bömer Ulf
Beddies Gerald
Foster Adrian
Schmidt Nicole
Nubbemeyer Reinhard
De Lourdes Mottier María
Original Assignee
Bayer Animal Health Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh, Bayer Pharma AG filed Critical Bayer Animal Health Gmbh
Publication of DOP2018000262A publication Critical patent/DOP2018000262A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al uso de indazoles sustituidos en el tratamiento y/o profilaxis de enfermedades alérgicas y/o inflamatorias en animales, especialmente para el tratamiento y/o profilaxis de la dermatitis atópica, Dermatitis Alérgica por pulgas, enfermedad intestinal inflamatoria, osteoartritis y dolor inflamatorio, enfermedad de las vías respiratorias recurrente no infecciosa, hipersensibilidad a los insectos, asma, enfermedad respiratoria, mastitis y endometritis en animales.
DO2018000262A 2016-06-01 2018-11-30 Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales DOP2018000262A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172544 2016-06-01

Publications (1)

Publication Number Publication Date
DOP2018000262A true DOP2018000262A (es) 2019-02-28

Family

ID=56097024

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000262A DOP2018000262A (es) 2016-06-01 2018-11-30 Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales

Country Status (25)

Country Link
US (2) US20200216413A1 (es)
EP (1) EP3464266B1 (es)
JP (1) JP7004677B2 (es)
KR (1) KR102547834B1 (es)
CN (1) CN109219603A (es)
AU (1) AU2017272505B9 (es)
BR (1) BR112018074927A2 (es)
CA (1) CA3025847A1 (es)
CL (1) CL2018003432A1 (es)
CO (1) CO2018013029A2 (es)
DK (1) DK3464266T3 (es)
DO (1) DOP2018000262A (es)
ES (1) ES2898771T3 (es)
IL (1) IL263132B (es)
MX (1) MX2018014899A (es)
MY (1) MY199070A (es)
PH (1) PH12018502530A1 (es)
PL (1) PL3464266T3 (es)
PT (1) PT3464266T (es)
RU (1) RU2743170C2 (es)
SG (1) SG11201809470RA (es)
SI (1) SI3464266T1 (es)
TW (1) TWI781935B (es)
UA (1) UA124237C2 (es)
WO (1) WO2017207481A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CA3016364A1 (en) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
SI3448846T1 (sl) 2016-04-29 2021-09-30 Bayer Pharma Aktiengesellschaft Sinteza indazolov
CU24593B1 (es) 2016-04-29 2022-05-11 Bayer Pharma AG Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida
SG11201810769QA (en) 2016-06-01 2018-12-28 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
BR112020007679A2 (pt) 2017-10-19 2020-10-20 Bayer Animal Health Gmbh uso de pirrolidonas heteroaromáticas fundidas para tratamento e prevenção de doenças em animais.
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
SG11202112870WA (en) 2019-05-23 2021-12-30 The Univ Of Montana Vaccine adjuvants based on tlr receptor ligands
CA3152167C (en) * 2019-09-24 2023-12-19 Guozhong YE Irak inhibitor and preparation method therefor and use thereof
EP3800188A1 (en) 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
JP7429032B2 (ja) 2019-12-24 2024-02-07 学校法人順天堂 間質性肺炎モデル非ヒト動物の作製方法
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
CN115300627B (zh) * 2021-05-08 2024-01-26 中南大学湘雅医院 钠-葡萄糖共转运蛋白2抑制剂的应用、一种药物组合物及其应用
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1671666A (zh) * 2002-07-31 2005-09-21 舍林股份公司 Vegfr－2和vegfr－3抑制性的邻氨基苯甲酰胺吡啶化合物
US20070179143A1 (en) 2003-06-25 2007-08-02 Je Il Pharmaceutical Co., Ltd. Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
JP2008523046A (ja) 2004-12-08 2008-07-03 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー メチレン誘導体
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
WO2007091107A1 (en) 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP2045253A4 (en) 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
CN101616910A (zh) 2006-09-07 2009-12-30 比奥根艾迪克Ma公司 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
ES2592713T3 (es) 2010-12-20 2016-12-01 Merck Serono S.A. Derivados de indazolil-triazol como inhibidores de IRAK
US8748432B2 (en) 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
JP6234444B2 (ja) 2012-05-21 2017-11-22 バイエル ファーマ アクチエンゲゼルシャフト チエノピリミジン類
WO2015017336A1 (en) * 2013-07-29 2015-02-05 OmniGen Research, L.L.C. Combination and method for administration to an animal
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
JP2017505337A (ja) * 2014-01-10 2017-02-16 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としてのインダゾール化合物
CN104093061B (zh) 2014-07-18 2020-06-02 北京智谷睿拓技术服务有限公司 内容分享方法和装置
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3288558B1 (en) * 2015-04-30 2022-05-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
SI3448846T1 (sl) * 2016-04-29 2021-09-30 Bayer Pharma Aktiengesellschaft Sinteza indazolov
CU24593B1 (es) * 2016-04-29 2022-05-11 Bayer Pharma AG Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)- piridin-2-carboxamida
SG11201810769QA (en) * 2016-06-01 2018-12-28 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Also Published As

Publication number Publication date
PH12018502530A1 (en) 2019-10-21
MX2018014899A (es) 2019-04-24
WO2017207481A8 (en) 2018-11-22
US20220204474A1 (en) 2022-06-30
AU2017272505A8 (en) 2018-11-29
JP7004677B2 (ja) 2022-01-21
AU2017272505A1 (en) 2018-11-15
AU2017272505B2 (en) 2021-10-07
IL263132B (en) 2022-04-01
BR112018074927A2 (pt) 2019-03-12
TW201808933A (zh) 2018-03-16
RU2018145860A3 (es) 2020-07-09
CO2018013029A2 (es) 2018-12-28
CN109219603A (zh) 2019-01-15
UA124237C2 (uk) 2021-08-11
IL263132A (en) 2018-12-31
ES2898771T3 (es) 2022-03-08
CA3025847A1 (en) 2017-12-07
US20200216413A1 (en) 2020-07-09
SG11201809470RA (en) 2018-11-29
EP3464266A1 (en) 2019-04-10
JP2019520348A (ja) 2019-07-18
WO2017207481A1 (en) 2017-12-07
AU2017272505B9 (en) 2021-10-28
EP3464266B1 (en) 2021-10-20
SI3464266T1 (sl) 2021-12-31
RU2018145860A (ru) 2020-07-09
TWI781935B (zh) 2022-11-01
MY199070A (en) 2023-10-12
KR20190015252A (ko) 2019-02-13
RU2743170C2 (ru) 2021-02-15
PL3464266T3 (pl) 2022-01-24
PT3464266T (pt) 2021-11-23
CL2018003432A1 (es) 2019-03-22
DK3464266T3 (da) 2021-11-22
KR102547834B1 (ko) 2023-06-26

Similar Documents

Publication Publication Date Title
DOP2018000262A (es) Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
ES2820879R1 (es) Composiciones para la liberación controlada de ingredientes activos y métodos de preparación de las mismas
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
CL2018000523A1 (es) Método para la inhibición de la absorción de lípidos y/o la promoción de excreción de lípidos usando d-psicosa
AR106644A1 (es) Composiciones nutricionales sinergísticas y usos de las mismas
EA201500873A1 (ru) Антимикробные композиции и способы их применения
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2018000433A1 (es) Procedimientos para mejorar la salud de peces de cultivo.
ES2699722R1 (es) Composicion para tratar enfermedades de las neuronas motoras y uso de la misma
MA46641A (fr) Méthodes et compositions permettant d'empêcher la transmission de maladies propagées par un vecteur
CO2017000745A2 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
ES1186511Y (es) Nebulizador para el tratamiento de las vias respiratorias
EA201890188A1 (ru) Новый бициклический липолантипептид, его получение и применение в качестве противомикробного средства
CL2018002368A1 (es) Formulaciones de oritavancina
GB2550750A (en) Anthelmintic compounds
CL2020001036A1 (es) Uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y prevención de enfermedades en los animales.
CO2019011285A2 (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso